Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Molecular Profiling a Must in Advanced NSCLC

Publish date:: September 10, 2019

Key clinical point: All patients with metastatic non–small cell lung cancer should be tested for targetable mutations/alterations.

Major finding: The 5-year overall survival for patients with ALK rearrangements now exceeds 40%.

Study details: A review of the literature on medical therapies for non–small cell lung cancer.

Disclosures: The review was supported in part by a grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center. Dr. Arbour reported serving as a consultant to AstraZeneca and nonfinancial research support from Novartis and Takeda. Dr. Riely reported grants and nonfinancial support from Pfizer, Roche/Genentech/Chugai, Novartis, Merck, and Takeda; a patent pending for an alternate dosing of erlotinib for which he has no right to royalties; and payments from the National Comprehensive Cancer Network to participate in a committee overseeing solicitation and selection of grants to be awarded by AstraZeneca.

Citation:

Arbour KC and Riely GJ. JAMA. 2019;322(8):764-74.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,